# Impact of Margin-accentuation IRE in Pancreatic Cancer

> **NCT02952859** · — · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 26 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **OTHER:** Irreversible electroporation

## Key facts

- **NCT ID:** NCT02952859
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2020-02-25
- **Final completion:** 2020-02-25
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** PI left hospital
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952859, "Impact of Margin-accentuation IRE in Pancreatic Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02952859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*